Zyversa Therapeutics Inc
(ZVSA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 528 | 72 | 1,612 | 1,531 | 123 |
| Other current assets | 169 | 98 | 0 | 0 | 0 |
| TOTAL | $996 | $549 | $2,110 | $1,716 | $390 |
| Non-Current Assets | |||||
| Intangibles | 0 | 18,648 | 18,648 | 18,648 | 18,648 |
| Other Non-Current Assets | 45 | 444 | 227 | 236 | 386 |
| TOTAL | $45 | $19,092 | $18,875 | $18,884 | $19,034 |
| Total Assets | $1,040 | $19,641 | $20,986 | $20,599 | $19,424 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,805 | 9,774 | 9,605 | 9,337 | 9,285 |
| Accrued Expenses | 2,961 | 2,915 | 2,399 | 1,894 | 2,257 |
| TOTAL | $12,766 | $12,690 | $12,004 | $11,231 | $11,542 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $852 | $852 | $852 | $855 |
| Total Liabilities | $12,766 | $13,541 | $12,855 | $12,083 | $12,397 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,096 | 8,096 | 4,773 | 2,568 | 2,344 |
| Common Shares | 1 | 1 | 0 | 0 | 0 |
| Retained earnings | -136,906 | -117,101 | -114,890 | -112,633 | -111,211 |
| Other shareholders' equity | -7 | -7 | -7 | -7 | -7 |
| TOTAL | $-11,726 | $6,100 | $8,130 | $8,516 | $7,027 |
| Total Liabilities And Equity | $1,040 | $19,641 | $20,986 | $20,599 | $19,424 |